Strata Critical Medical, Inc. (SRTA) Insider Trading

Last 12 months

Insiders bought $98k and sold $507k on the open market.

75% of the selling was scheduled in advance under 10b5-1 plans.

Net open-market

−$409k

2 buys · 5 sales

Under a 10b5-1 plan

75%

of the value sold

Insiders who bought / sold

2 / 2

executives and directors

Last open-market buy

Dec 2025

Dec 9, 2025

Get an email when SRTA's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 10	Reginald Love Director	SoldNo plan	5,091	$5.75	$29k	3.4%	Form 4
May 21 – 22	Amir Cohen Chief Accounting Officer	Sold10b5-1 plan 2 parts	50,875	$5.89 average	$299k	25%	Form 4
May 11	Amir Cohen Chief Accounting Officer	Sold10b5-1 plan	14,306	$5.79	$83k	6.6%	Form 4
Dec 9, 2025	William A. Heyburn Co-CEO and CFO	Bought	17,000	$4.47	$76k	1.2%	Form 4
Dec 5, 2025	Andrew Lauck Director	Bought	5,000	$4.37	$22k	3.8%	Form 4
Nov 20, 2025	Reginald Love Director	SoldNo plan	11,000	$4.37	$48k	8.8%	Form 4
Nov 19, 2025	Reginald Love Director	SoldNo plan	11,000	$4.31	$47k	8.1%	Form 4
Aug 4, 2025	Melissa M. Tomkiel President and General Counsel	Sold10b5-1 plan	47,995	$4.94	$237k	4.0%	Form 4
Aug 4, 2025	William A. Heyburn Chief Financial Officer	Sold10b5-1 plan	46,918	$4.94	$232k	3.4%	Form 4
Jun 9, 2025	Melissa M. Tomkiel President and General Counsel	Sold10b5-1 plan	100,000	$4.08	$408k	8.2%	Form 4
Jun 9, 2025	William A. Heyburn Chief Financial Officer	Sold10b5-1 plan	100,000	$4.07	$407k	7.0%	Form 4
Jan 6, 2025 – Jan 7, 2025	William A. Heyburn Chief Financial Officer	Sold10b5-1 plan 2 parts	104,570	$5.02 average	$525k	7.0%	Form 4
Dec 13, 2024	Reginald Love Director	SoldNo plan	5,091	$4.05	$21k	4.8%	Form 4
Dec 13, 2024	John Borthwick Director	SoldNo plan	78,291	$4.00	$313k	32%	Form 4
Dec 9, 2024	Melissa M. Tomkiel President and General Counsel	Sold10b5-1 plan	22,486	$5.01	$113k	2.2%	Form 4
Dec 9, 2024	William A. Heyburn Chief Financial Officer	Sold10b5-1 plan	39,285	$5.02	$197k	2.9%	Form 4
Dec 2, 2024 – Dec 4, 2024	Amir Cohen Chief Accounting Officer	SoldNo plan 2 parts	10,150	$4.45 average	$45k	14%	Form 4
Nov 29, 2024	William A. Heyburn Chief Financial Officer	Sold10b5-1 plan	23,815	$5.02	$120k	1.7%	Form 4
Nov 27, 2024 – Nov 29, 2024	Melissa M. Tomkiel President and General Counsel	Sold10b5-1 plan 3 parts	111,377	$4.50 average	$502k	9.5%	Form 4
Nov 14, 2024	Robert S Wiesenthal Chief Executive Officer	SoldNo plan	2,100,000	$3.22	$6.76M	30%	Form 4
Nov 12, 2024	Melissa M. Tomkiel President and General Counsel	Sold10b5-1 plan	44,621	$3.40	$152k	3.7%	Form 4

Aug 10No plan
Reginald Love
Director · sold 5,091 at $5.75
$29k
3.4% of stake
May 21 – 2210b5-1 plan
Amir Cohen
Chief Accounting Officer · sold 50,875 at avg $5.89
$299k
25% of stake
May 1110b5-1 plan
Amir Cohen
Chief Accounting Officer · sold 14,306 at $5.79
$83k
6.6% of stake
Dec 9, 2025
William A. Heyburn
Co-CEO and CFO · bought 17,000 at $4.47
$76k
1.2% of stake
Dec 5, 2025
Andrew Lauck
Director · bought 5,000 at $4.37
$22k
3.8% of stake
Nov 20, 2025No plan
Reginald Love
Director · sold 11,000 at $4.37
$48k
8.8% of stake
Nov 19, 2025No plan
Reginald Love
Director · sold 11,000 at $4.31
$47k
8.1% of stake
Aug 4, 202510b5-1 plan
Melissa M. Tomkiel
President and General Counsel · sold 47,995 at $4.94
$237k
4.0% of stake
Aug 4, 202510b5-1 plan
William A. Heyburn
Chief Financial Officer · sold 46,918 at $4.94
$232k
3.4% of stake
Jun 9, 202510b5-1 plan
Melissa M. Tomkiel
President and General Counsel · sold 100,000 at $4.08
$408k
8.2% of stake
Jun 9, 202510b5-1 plan
William A. Heyburn
Chief Financial Officer · sold 100,000 at $4.07
$407k
7.0% of stake
Jan 6, 2025 – Jan 7, 202510b5-1 plan
William A. Heyburn
Chief Financial Officer · sold 104,570 at avg $5.02
$525k
7.0% of stake
Dec 13, 2024No plan
Reginald Love
Director · sold 5,091 at $4.05
$21k
4.8% of stake
Dec 13, 2024No plan
John Borthwick
Director · sold 78,291 at $4.00
$313k
32% of stake
Dec 9, 202410b5-1 plan
Melissa M. Tomkiel
President and General Counsel · sold 22,486 at $5.01
$113k
2.2% of stake
Dec 9, 202410b5-1 plan
William A. Heyburn
Chief Financial Officer · sold 39,285 at $5.02
$197k
2.9% of stake
Dec 2, 2024 – Dec 4, 2024No plan
Amir Cohen
Chief Accounting Officer · sold 10,150 at avg $4.45
$45k
14% of stake
Nov 29, 202410b5-1 plan
William A. Heyburn
Chief Financial Officer · sold 23,815 at $5.02
$120k
1.7% of stake
Nov 27, 2024 – Nov 29, 202410b5-1 plan
Melissa M. Tomkiel
President and General Counsel · sold 111,377 at avg $4.50
$502k
9.5% of stake
Nov 14, 2024No plan
Robert S Wiesenthal
Chief Executive Officer · sold 2,100,000 at $3.22
$6.76M
30% of stake
Nov 12, 202410b5-1 plan
Melissa M. Tomkiel
President and General Counsel · sold 44,621 at $3.40
$152k
3.7% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch SRTA, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Services-Health Services

TALKTalkspace Inc.

DCGODocGo Inc.

OMDAOmada Health, Inc.

WGSGeneDx Holdings Corp.

USPHU.S. Physical Therapy Inc.

INNVInnovAge Holding Corp.

PNTGThe Pennant Group, Inc.

PIIIP3 Health Partners Inc.

Spot a number that looks wrong? Check it in SRTA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing SRTA

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.